Antibiotic Safety in Heart Failure with Reduced Ejection Fraction

Key Safety Considerations and Management

• The European Society of Cardiology recommends ARBs as alternatives to ACE inhibitors for symptomatic HFrEF patients, and valsartan is appropriate therapy for patients with EF 35% and should be continued 1, 2
• The American College of Cardiology and American Heart Association guidelines note that calcium channel blockers like amlodipine are not indicated as routine treatment for heart failure but do not prohibit their use when prescribed for hypertension 3
• Thiazide diuretics are appropriate for symptom management in heart failure, according to the American College of Cardiology and American Heart Association guidelines 3
• Before initiating antibiotics, assess current volume status and symptoms, check baseline renal function and electrolytes, and document baseline weight, as recommended by the European Society of Cardiology 1, 4, 5
• Daily weight monitoring is essential to detect early fluid retention or depletion during antibiotic therapy, according to the American College of Cardiology and American Heart Association guidelines 6
• Red flags requiring urgent evaluation include weight gain >2-3 pounds in 24 hours or >5 pounds in one week, new or worsening dyspnea, severe or persistent diarrhea, and symptomatic hypotension or dizziness, as noted by the American College of Cardiology and American Heart Association guidelines 3
• The European Society of Cardiology recommends that guideline-directed medical therapy, including valsartan, should be continued during antibiotic treatment as it provides mortality benefit in HFrEF 1, 2
• NSAIDs and COX-2 inhibitors are specifically contraindicated in heart failure due to increased risk of worsening and hospitalization, according to the European Society of Cardiology 1, 7, 4